GOSS News and Press, Gossamer Bio Inc. From 04/03/20

New York, New York--(Newsfile Corp. - April 3, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities ...

BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockesq.com ), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers and directors ...

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP ) initiated with Buy rating and $12 (143% upside) price target at Nomura Instinet. More news on: Corbus Pharmaceuticals Holdings, Inc., Bruker Corporation, Danaher Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

BOSTON, March 25, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP ( www.blockesq.com ), a national securities litigation firm, announces that it has opened an investigation into Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers for potential securities fraud.  Investors ...

Gossamer Bio (NASDAQ: GOSS ): Q4 GAAP EPS of -$0.89 misses by $0.07 . More news on: Gossamer Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– Clinical trial results for all four clinical-stage product candidates in target areas of immunology, inflammation and oncology expected in 2020 – – Cash, cash equivalents and marketable securities totaled $401.8 million at year-end 2019 – Gossam...

Plan to advance AKB-9778 topical formulation into a Phase 2 trial in open angle glaucoma with top line results expected during the first quarter of 2021 Conference Call and Webcast Today, March 16, 2020 at 8:30 a.m. EST CINCINNATI, March 16, 2020 (GLOBE NEWSWIRE) -- Aerpio Phar...

Quick Take Lyra Therapeutics ( LYRA ) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of treatment candidates for chronic rhinosinusitis patients. LYRA is in Phase 2 trials for its lead cand...

The investment research arm of Barclays (NYSE: BCS ,LSE:BARC) is not worried about drug pricing concerns in the US; instead, it has a positive outlook for the country’s biopharma industry. On Wednesday (February 26), Barclays Capital launched its coverage of the US biopharma space w...

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co...